Free Trial
NASDAQ:GTBP

GT Biopharma (GTBP) Stock Price, News & Analysis

GT Biopharma logo
$0.94 +0.01 (+1.18%)
Closing price 09/5/2025 04:00 PM Eastern
Extended Trading
$0.88 -0.05 (-5.85%)
As of 09/5/2025 07:59 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

About GT Biopharma Stock (NASDAQ:GTBP)

Key Stats

Today's Range
$0.89
$0.95
50-Day Range
$0.90
$3.58
52-Week Range
$0.88
$4.10
Volume
3.23 million shs
Average Volume
124,710 shs
Market Capitalization
$3.34 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$11.00
Consensus Rating
Strong Buy

Company Overview

GT Biopharma Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
44th Percentile Overall Score

GTBP MarketRank™: 

GT Biopharma scored higher than 44% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    GT Biopharma has received a consensus rating of Strong Buy. The company's average rating score is 3.50, and is based on 1 buy rating, no hold ratings, and no sell ratings.

  • Upside Potential

    GT Biopharma has a consensus price target of $11.00, representing about 1,070.2% upside from its current price of $0.94.

  • Amount of Analyst Coverage

    GT Biopharma has received no research coverage in the past 90 days.

  • Read more about GT Biopharma's stock forecast and price target.
  • Earnings Growth

    Earnings for GT Biopharma are expected to grow in the coming year, from ($6.79) to ($2.11) per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of GT Biopharma is -0.23, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of GT Biopharma is -0.23, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Read more about GT Biopharma's valuation and earnings.
  • Percentage of Shares Shorted

    8.59% of the float of GT Biopharma has been sold short.
  • Short Interest Ratio / Days to Cover

    GT Biopharma has a short interest ratio ("days to cover") of 2.8, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in GT Biopharma has recently decreased by 7.55%, indicating that investor sentiment is improving significantly.
  • Dividend Yield

    GT Biopharma does not currently pay a dividend.

  • Dividend Growth

    GT Biopharma does not have a long track record of dividend growth.

  • Percentage of Shares Shorted

    8.59% of the float of GT Biopharma has been sold short.
  • Short Interest Ratio / Days to Cover

    GT Biopharma has a short interest ratio ("days to cover") of 2.8, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in GT Biopharma has recently decreased by 7.55%, indicating that investor sentiment is improving significantly.
  • News Coverage This Week

    MarketBeat has tracked 2 news articles for GT Biopharma this week, compared to 0 articles on an average week.
  • Search Interest

    1 people have searched for GTBP on MarketBeat in the last 30 days.
  • MarketBeat Follows

    16 people have added GT Biopharma to their MarketBeat watchlist in the last 30 days. This is an increase of 1,500% compared to the previous 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, GT Biopharma insiders have not sold or bought any company stock.

  • Percentage Held by Insiders

    Only 3.40% of the stock of GT Biopharma is held by insiders.

  • Percentage Held by Institutions

    Only 8.15% of the stock of GT Biopharma is held by institutions.

  • Read more about GT Biopharma's insider trading history.
Receive GTBP Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for GT Biopharma and its competitors with MarketBeat's FREE daily newsletter.

By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

GTBP Stock News Headlines

GT Biopharma (NASDAQ:GTBP) Upgraded to "Hold" at Wall Street Zen
“Sell Nvidia before earnings”
Eric Fry just went live with one of his most controversial calls yet: “Sell Nvidia.” While Wall Street has been chasing the AI giant, Eric says its biggest customers are now its biggest competitors — and that could spell trouble ahead. Instead, he’s urging investors to consider a little-known hardware company that’s already starting to take off. In fact, while Nvidia has slipped over the past 30 days, this “off-the-radar” stock is up 18% — and Eric believes the run is just beginning.tc pixel
GT Biopharma Inc
GT Biopharma Reports Second Quarter 2025 Financial Results
GT Biopharma, Inc. (GTBP) - Yahoo Finance
See More Headlines

GTBP Stock Analysis - Frequently Asked Questions

GT Biopharma's stock was trading at $3.05 at the start of the year. Since then, GTBP shares have decreased by 69.2% and is now trading at $0.94.

GT Biopharma, Inc. (NASDAQ:GTBP) posted its quarterly earnings data on Thursday, August, 14th. The company reported ($0.55) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.68) by $0.13.

GT Biopharma shares reverse split before market open on Monday, February 5th 2024.The 1-30 reverse split was announced on Monday, February 5th 2024. The number of shares owned by shareholders was adjusted after the market closes on Monday, February 5th 2024. An investor that had 100 shares of stock prior to the reverse split would have 3 shares after the split.

Top institutional shareholders of GT Biopharma include Bank of Montreal Can (2.83%). Insiders that own company stock include Michael Martin Breen and Manu Ohri.
View institutional ownership trends
.

Shares of GTBP stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that GT Biopharma investors own include NVIDIA (NVDA), Advanced Micro Devices (AMD), Adobe (ADBE), Broadcom (AVGO), Meta Platforms (META), CrowdStrike (CRWD) and Intel (INTC).

Company Calendar

Last Earnings
8/14/2025
Today
9/07/2025
Next Earnings (Estimated)
11/13/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
MED - BIOMED/GENE
Sub-Industry
Pharmaceutical Products
Current Symbol
NASDAQ:GTBP
Previous Symbol
OTCMKTS:OXISD
CIK
109657
Fax
N/A
Employees
8
Year Founded
1965

Price Target and Rating

High Price Target
$11.00
Low Price Target
$11.00
Potential Upside/Downside
+1,070.2%
Consensus Rating
Strong Buy
Rating Score (0-4)
3.50
Research Coverage
2 Analysts

Profitability

EPS (Trailing Twelve Months)
($4.07)
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
-$13.16 million
Net Margins
N/A
Pretax Margin
N/A
Return on Equity
-1,804.34%
Return on Assets
-200.12%

Debt

Debt-to-Equity Ratio
N/A
Current Ratio
2.76
Quick Ratio
2.76

Sales & Book Value

Annual Sales
N/A
Price / Sales
N/A
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
($0.75) per share
Price / Book
-1.25

Miscellaneous

Outstanding Shares
3,557,000
Free Float
3,436,000
Market Cap
$3.34 million
Optionable
No Data
Beta
1.36

Social Links

The Best High-Yield Dividend Stocks for 2025 Cover

Discover the 10 Best High-Yield Dividend Stocks for 2025 and secure reliable income in uncertain markets. Download the report now to identify top dividend payers and avoid common yield traps.

Get This Free Report

This page (NASDAQ:GTBP) was last updated on 9/7/2025 by MarketBeat.com Staff
From Our Partners